RT @Alahmari_MD: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) fo…
A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia !! https://t.co/XhOC3JNSYP
RT @BibliotecaHUVH: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen)…
A Phase I-II Study of Plerixafor in Combination w/ Fludarabine, Idarubicin, Cytarabine, & G-CSF (PLERIFLAG Regimen) for the Treatment of Patients with the First Early-Relapsed or Refractory Acute Myeloid Leukemia https://t.co/Y2DVJ1quko
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. https://t.co/jgPPXp7E72 #leukemia http
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia #hvhebron #hemat https://t.co/NXx4U14px
PubMed Cáceres: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. https://t.co/ftbdlblX6